High-Tech Gründerfonds Management GmbH. (8/18/17). "Press Release: Crowdfunding Triggers Capital Increase of 800,000 Euros at Rodos Biotarget".

	Organisation	High-Tech Gründerfonds (HTGF) (Group)
	Today	High-Tech Gründerfonds Management GmbH
	Organisation 2	Rodos BioTarget GmbH
	Product	Seedmatch crowdfunding platform
	Product 2	TargoSphere® nanocarrier technology
	Person	Gies, Otto H. (3B Scientifc)
	Person 2	Furch, Marcus (Rodos BioTarget 200905 CEO)

After his initial crowd investment, medical entrepreneur and business angel Otto H. Gies invests in the biopharmaceutical company via direct shareholding.

Rodos Biotarget is the first German life-science company to initiate crowdfunding campaigns via two crowd platforms. In 2016, a first round took place with Seedmatch, and a current financing round is running with aescuvest. With this approach, in addition to raising capital for further corporate development, Rodos Biotarget has two further objectives:

First, impact investing in the area of health economy will be opened up also for private investors within their bounds of possibilities. Second, the company wants to access business partners, collaborators, customers, and private equity through the level of attention created by crowdfunding. This has been achieved with the company entry of medical entrepreneur Otto H. Gies.

Over almost 30 years, managing partner Otto H. Gies developed the 3B Scientific company group into a specialty provider offering educational materials for medical training in more than one hundred countries. The company group was recently sold to an American private equity company.

Otto H. Gies on his investment: ” Rodos Biotarget’s new nanomedicine developments for addressing diabetes as well as various liver diseases in particular have convinced me.”

Dr. Marcus Furch, Rodos’ managing partner, commented: “With Mr. Gies we are happy to having been able to win over an experienced entrepreneur with a valuable international network. We are greatly looking forward to working closely together with him.”

This financing round is further accompanied by High-Tech Gründerfonds and Hannover Investimpuls Fonds.

About Rodos Biotarget GmbH

Rodos Biotarget GmbH (a limited liability company according to German law) has developed a platform technology called TargoSphere® for nanocarrier-enabled targeted and efficient drug delivery. This technology is suitable for prophylactic and therapeutic applications in various disease areas of high medical need. These include cancers, chronic infections, autoimmune diseases, and neurological disorders. For commercializing its patented technology platform, the company primarily relies on collaborations with major pharmaceutical companies. In addition, the company promotes in-house therapy developments including TargoBioticsTM for the treatment of intracellular bacterial infections, TargoVirTM for the treatment of chronic viral diseases, and further nanomedicines for the treatment of type 2 diabetes and liver diseases such as acute liver failure, liver fibrosis, urea cycle deficiencies and liver cancer.

Contact details:

MBA Rodos Biotarget GmbH
Dr. Marcus Furch
CEO / Managing Director Medical Park Hannover
Feodor-Lynen-Str. 31
D-30625 Hannover
Tel.: +49 (511) 72738835
Fax: +49 (511) 2147076
m.furch@biotargeting.eu
www.biotargeting.eu

About HTGF

High-Tech Gründerfonds (HTGF) is Germany’s most active seed stage investor. With about EUR 820 million under management in three funds, it provide financing for technology-driven companies active in a wide range of fields, including robotics, IoT and energy, Medtech and Biotech, chemicals and software. Investors in this public-private partnership include the German Federal Ministry of Economics and Energy, the KfW, and strategic corporate investors.

Contact details:
High-Tech Gründerfonds Management GmbH
Dr. Martin Pfister
Schlegelstraße 2
53113 Bonn
Tel: +49 (228) 823 001-00
Fax: +49 (228) 823 000-50
info@high-tech-gruenderfonds.de
www.high-tech-gruenderfonds.de

Record changed: 2023-06-05